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Abstract
The main goal of this project was to examine the differences in perioperative
hyperglycemia treatment received by patients with a diagnosis of diabetes mellitus (DM) and
patients without a diagnosis of diabetes (NDM); and how these treatment differences can affect
the length of hospital stay. Studies have revealed that, when comparing DM and NDM patients
with the same degree of perioperative hyperglycemia, NDM patients suffer worse outcomes. It
has been suggested in previous research that this may be because NDM patients receive
treatment that does not measure up to the standard of care treatment that DM patients receive. In
this project, we study these standard of care discrepancies between DM and NDM patients, in
order to examine the difference in postoperative hospital length of stay (LOS).
We conducted a retrospective cohort study, using a subset of data comprised of inpatients
who underwent a broad spectrum of surgery types at Nebraska Medicine over a period of twenty
months. All patients in the study experienced perioperative hyperglycemia. Roughly half of them
were DM patients and roughly half were NDM patients. We performed bivariate regression
analysis on all available covariates in the data set in order to find candidates for final linear and
logistic regression models. We also performed a time-to-event survival analysis to see if different
lengths of stay among the two groups of patients were explained by possible differences in time
lags between hyperglycemia trigger and insulin administration. We aimed to find whether
aspects of glucose control practices were associated with hyperglycemic NDM patients
experiencing longer LOS than DM patients. This information may bolster existing study
conclusions and better assist us in understanding barriers to glucose control measures in NDM
patients.

Introduction
The average American undergoes a total of approximately 9 surgical procedures over the
course of an 85-year lifetime (Lee & Gawande, 2008). Of all surgical patients, 30-40 percent will
develop hyperglycemia at some point during the perioperative period; and one in four patients
with hyperglycemia will suffer an adverse outcome in the perioperative setting (DeFelice &
Thompson, 2016). Multiple studies have identified the link between poorly managed
hyperglycemia in the perioperative setting and adverse outcomes, including morbidity, postoperative infections, increased length of hospital stay, and mortality (DeFelice & Thompson,
2016, Kwon et al, 2013, Umpierrez et al, 2011).
Furthermore, the association between perioperative hyperglycemia and adverse outcomes
is stronger among patients without diabetes (NDM patients) than patients with diabetes (DM
patients), even with similar elevations in blood glucose level (Kotagal et al, 2013; Kwon et al,
2013; Frisch et al, 2010). One possible explanation is that NDM patients with perioperative
hyperglycemia receive inferior treatment compared to DM patients. The purpose of this study
was to examine the differences in perioperative hyperglycemia treatment received by DM
patients and NDM patients; and how these differences can affect the length of hospital stay
(LOS). Thus, our main research question was posed: what differences in perioperative
hyperglycemia treatment, if any, were associated with the phenomenon that NDM patients
experience longer lengths of stay than DM patients?

Importance
Over 50 million inpatient surgical procedures were performed in the United States in
2010 and this number continues to increase every year (Johns Hopkins Medicine, n.d.). The
rising number of surgeries each year in the U.S. leads to a relatively large number of

complications affecting the general health of the public. Even an incremental of reduction in
adverse outcomes for those experiencing perioperative hyperglycemia could help reduce overall
healthcare costs in the U.S., and lead to a sizeable reduction in complications affecting the
portion of the public who undergo surgery each year.
If this study lends credence to the belief that NDM patients receive inferior treatment that
leads to worse surgical outcomes, it may inform changes in hospital systems and provider
practices with regard to the standard of perioperative hyperglycemia treatment. If this and other
research leads to changes in the SOC for NDM patients experiencing perioperative
hyperglycemia, then it stands to reason that inpatient surgical outcomes for NDM patients as a
whole will improve. Better outcomes, including decreased length of hospital stay (LOS), could
be extremely beneficial to public health in general; as a growing number of the public undergo
inpatient surgeries in the U.S. each year. Thus, we believe that the importance of this research
project from a patient health and public health standpoint is evident.

Objectives
Our main goal was to examine treatment standards for perioperative hyperglycemia in
relation to the length of stay for DM and NDM surgical inpatients. To address this goal, we
focused on the objectives of applying descriptive and inferential methodologies according to the
retrospective cohort study design. To help us achieve the descriptive methodological objective,
we conducted data analyses using t-test to compare numerical demographic characteristics
between diabetes status groups; and Chi-square test for the categorical characteristics. To
achieve the inferential methodological objective, we conducted a multivariate linear regression
for the duration of hospital stay (LOS), accounting for patient risk, surgical risk, and other
variables that were deemed to be significant in the analysis phase of building our predictive

model.
We utilized multivariate linear regression to test the hypothesis that, on average,
hyperglycemic NDM patients have longer lengths of stay than hyperglycemic DM patients. We
also utilized multivariate logistic regression to test the hypothesis that a lower proportion of
NDM patients receive the SOC for hyperglycemia compared to DM patients. Finally, we utilized
a multivariate Cox regression for the time from initial blood glucose reading > 140 mg/dL2
(hyperglycemic trigger) until the administration of insulin therapy. This tested the hypothesis
that the mean wait time between the hyperglycemic trigger and administration of insulin is
longer for NDM patients than it is for DM patients.

Background
A number of studies show that perioperative hyperglycemia is associated with a host of
adverse outcomes (DeFelice & Thompson, 2016, Kwon et al, 2013, Umpierrez et al, 2011).
Some studies have focused only on DM patients (Buchleitner et al, 2012; Mcalister et al, 2003;
Furnary & Wu, 2004). While others have compared perioperative hyperglycemia in DM and
NDM patients (Umpierrez, 2002; Kotagal et al, 2015). Those studies provide evidence that
perioperative hyperglycemia has divergent effects on NDM compared to DM patients. This
disparity in adverse outcomes has been confirmed for infection, morbidity and mortality.
Increased hospital LOS post-surgery has also been found to differ between DM and NDM
patients with hyperglycemia (Kotagal et al, 2013). As previously cited from DeFelice and
Thompson (2016), 30 to 40% of patients will experience hyperglycemia at some point in the
perioperative period. Of those who experience hyperglycemia during the perioperative period,
25% will suffer an adverse outcome. Perioperative hyperglycemia, regardless of diabetes status,
has been found to be associated with adverse outcomes in numerous types of surgery, including

vascular surgeries, mastectomies and neurosurgeries (Kwon et al, 2013).
A post-operative blood glucose level greater than 140mg/dL2, representing mild
hyperglycemia, is present in as many as 40% of patients undergoing non-cardiac surgery; and
25% of patients with hyperglycemia have a blood glucose level of at least 180 mg/dL2 (Kwon et
al, 2013). Worsening hyperglycemia has been found to be independently predictive of rising
mortality (Kwon et al, 2013). Increasing blood glucose levels have been shown to be directly
associated with increased hospital costs, wound infections, death and increased lengths of
hospital stay (Furnary, Wu & Bookin, 2004). Simha and Shah (2019) found that perioperative
hyperglycemia is also associated with pneumonia, sepsis, and cardiovascular events, as well as
confirmed its association with increased length of stay and other adverse outcomes.
The phenomenon of NDM patients suffering from higher rates of complications from
perioperative hyperglycemia has also been observed repeatedly in the scientific literature. A
study by Kotagal et al (2015) found that, although DM patients are at higher risk of adverse
outcomes from surgery than NDM patients, NDM patients who develop perioperative
hyperglycemia are at even higher risk. Other studies have shown that NDM patients with
perioperative hyperglycemia have nearly two times the risk of re-operative interventions,
infections, increased length of stay, and in-hospital death than do DM patients (Kwon et al,
2013). The occurrence of death is also shown in a study by Frisch et al. (2010), who noted the
increased risk of 30-day mortality following surgery for NDM patients who experienced
perioperative hyperglycemia, compared to DM patients who experienced perioperative
hyperglycemia. It has been suggested that differences in physiological responses/processes and
differences in treatment approach for DM and NDM patients are mechanisms that might help to
explain this phenomenon. For example, NDM patients may require a more extreme stress and

inflammatory response to result in the same blood glucose elevation than is required for DM
patients. Hyperglycemia may also have a more pronounced effect on NDM patients because it is
a novel stressor to them. Insulin administration may also be tolerated poorly for a similar reason
(Kotagal et al, 2013). Related to this is the fact that insulin therapy might not be used as
aggressively, and blood glucose testing might not be used as often on NDM patients. An
illustration of the phenomenon of increased adverse outcome rates for perioperative
hyperglycemic patients from the study by Kotagal et al (2013) can be seen in Figure 1.
This same study
suggested that the underlying
reason for the increased risk of
adverse outcomes for NDM
patients may be the under-use of
insulin for this group. In fact, it
is widely noted in the literature
that DM patients experiencing
perioperative hyperglycemia
may receive SOC management more routinely than NDM patients experiencing hyperglycemia.
This may be because care providers have a hyperglycemic control regimen planned prior to
surgery in patients known to have diabetes. In NDM patients, they likely do not monitor blood
glucose as closely and may not focus on hyperglycemia even when it is detected. One study
found that glucose measurement only occurred in 59% of hospital patients; with only 54% of
those with hyperglycemia receiving insulin therapy at all (Kwon et al, 2013). This seems to lend
credence to the belief that NDM patients are simply treated differently than DM patients when it

comes to issues related to increasing blood glucose. Confirming this finding, one study found
that between the diabetes status groups, NDM patients are simply less likely than DM patients to
receive insulin therapy at each increasing blood glucose level (Kotagal et al, 2015). A related
issue is the prevalence of undiagnosed diabetes. One phenomenon that has been increasing is that
undiagnosed insulin resistance is often not identified until the day of surgery (Kwon et al, 2013).
This has been confirmed by other studies that have shown that the diagnosis of diabetes is
commonly not revealed until a patient is in the surgical setting. By that time, it may be too late
for a medical team to provide hyperglycemia management that is as effective as it is for patients
known to have diabetes. Again, in cases of a new diabetes diagnosis, glucose monitoring may not
be as timely or as frequent as it is for known DM patients; thus resulting in a higher rate of
adverse outcomes (Kotagal et al. 2015).
Appropriate treatment of hyperglycemia appears to reduce the risk of perioperative
adverse events. One study concluded that in both diabetes status groups, improvement in the
control of blood glucose level has positive effects on mortality and morbidity (Schmeltz et al,
2007). Improved glucose control also reduces the duration of post-operative hospital LOS
(Frisch et al, 2010). Other studies suggest that good glucose control is beneficial to reducing
post-op mortality and length of stay; and that the SOC to manage perioperative hyperglycemia in
DM patients may guide the management of NDM patients (Simha & Shah, 2019). If these
problems were noted and tested more often during the pre-operative period, and insulin control
was used more often for all patients experiencing perioperative hyperglycemia (regardless of
diabetes status), then the rate of adverse outcomes for NDM patients might decrease.

Methods
Among patients in our study cohort, a status of diabetes was defined by a documentation

of diabetes mellitus (type 1 or 2) in the medical record at the time of index admission. Length of
hospital stay (LOS) was defined as the length of time a patient spent in the hospital from
admission time until discharge time, as documented in the medical record. The hyperglycemic
trigger was the time at which the patient had an initial blood glucose reading > 140 mg/dL2.
Insulin administration was defined as the first time basal or short-acting insulin was administered
to the patient. In order to study the standard of care for hyperglycemia, we created a dichotomous
SOC variable, using the definition of SOC put forth by the American Diabetes Association
(ADA, 2016). This states that for the SOC to be delivered in cases of perioperative
hyperglycemia, all of the following three criteria must be met: 1) four times daily point of care
blood glucose testing ordered within 24 hours of hyperglycemic trigger; 2) basal (long-acting)
insulin administered within 24 hours of trigger; 3) short-acting insulin administered within 24
hours of trigger. Finally, patients fell into one of three American Society of Anesthesiologists
Physical Status Classifications (ASA Class): mild systemic disease, severe systemic disease, and
incapacitating disease.
Increased hospital length of stay (LOS) has been confirmed as an adverse outcome of
perioperative hyperglycemia in the scientific literature. Because our final data set had complete
and reliable data on this specific adverse outcome, our research focused on LOS. As previously
stated, one of our aims was to test the hypothesis that, on average, hyperglycemic NDM patients
have longer lengths of hospital stay than hyperglycemic DM patients. Therefore, the statistical
inferences we performed focused on LOS as the continuous outcome variable. Another goal was
to test the hypothesis that a lower proportion of NDM patients are receiving the SOC for
hyperglycemia than are DM patients. Also, whether a possible difference between the two
diabetes status groups in the treatment of perioperative hyperglycemia were associated with LOS

in our sample of patient records.
For this project, we performed a retrospective cohort study; with data sets provided by
the Department of General Internal Medicine (GIM) at the University of Nebraska Medical
Center (UNMC) in Omaha, Nebraska. Some of the data sets used were extracted directly from
the Electronic Medical Record (EMR); and some were generated through direct chart review
completed by a member of the GIM team. This chart review data was collected and managed
using REDCap electronic data capture tools hosted at UNMC. REDCap service and support is
provided by the Research Information Technology Office (RITO), which is funded by the Vice
Chancellor for Research. All data files were exported to Microsoft Excel. We merged all
applicable data sets into one final set with one record per Medical Record Number (MRN). The
task of importing, cleaning and merging of the separate data files was performed using SAS 9.4
(SAS Institute, Carrey, NC). SAS was also used to perform all of our statistical analyses. For
inclusion into our final data set, patients met all of the following criteria: they underwent a
surgical procedure at Nebraska Medicine between December 1, 2016 and August 31, 2017; they
experienced a perioperative glucose reading of at least 180 mg/dL2; they were at least 19 years of
age during the perioperative period; and they were admitted to the hospital as a result their
surgery and had a length of stay of at least 72 hours.
The study was powered for our main research hypothesis, which was to explore the effect
of diabetes status on LOS. For the power and sample size calculations to help us determine a
sufficient record count for each diabetes status group, we used the two-sided, un-paired t-test, for
power of 80% (0.8) and level of significance, 0.05. Both needed power and group sample sizes
were satisfied with our final data set; including 507 total patient records (n1 = 268 DM patients;
n2 = 239 NDM patients).

Since data extraction was already completed, it was not part of this project. However, the
merging of the data and the creation of SOC component and dichotomous variables based on
ADA criteria was paramount to the success of the project. Statistical modeling included
multivariate linear regression for our continuous response variable (LOS), and multivariate
logistic regression for our dichotomous response variable (SOC). The time-to-event (insulin
administration) analysis was completed using the Kaplan-Meyer approach and the extended Cox
regression model. Where appropriate, transformation of some continuous variables was
performed, so as to meet linear regression modeling assumptions. Multivariate linear, logistic
and extended Cox regression model results are summarized in subsequent tables and in the
forthcoming results section. The level of significance in our final models was capped at alpha =
0.05.
Finally, the linear regression analysis for LOS was consistent with previously published
studies. Many studies referenced in the background section performed linear regressions to
examine associations between covariates and LOS. We have noted that LOS is highly skewed;
and therefore discussed the best way to handle LOS as an outcome. We found one study that,
rather than using linear regression on LOS, they used Poisson and negative binomial regression
(Carter & Potts, 2014). However, we found that many of the resources we previously cited used
linear regression for LOS analysis, as well as additional studies we researched (Taiwo et al,
2016; Szafranski et al, 2014). We also found a specific example of transforming LOS in
bivariate and multivariate linear regressions, similar to our approach for this study (Freidl, Benda
& Friedrich, 2015). Thus, literature precedence and statistical experience make us confident in
how we handled LOS in our analyses.

Statistics
Final models used to address our research hypotheses were derived from multivariate
linear regression, multivariate logistic regression, and multivariate extended Cox regression
analysis. In order to find covariates to test for inclusion into our linear regression model, we
performed bivariate linear regression analysis for each notable continuous variable in our data set
independently, with LOS being the outcome variable. We ran single and multifactor Analyses of
Variance (ANOVA) to compare all categorical covariates independently with LOS. All variables
with a p-value less than or equal to 0.20 were considered viable for testing in our regression
models.
To answer our hypothesis regarding whether or not NDM patients have significantly
longer lengths of stay than DM patients, we performed a multivariate linear regression. Our
initial regression to test this hypothesis started with all of the candidate variables from the
bivariate analyses. We then used manual backward selection, which involved removing the
covariate with the highest p-value, rerunning the model without said covariate, and repeating this
process until the model included only statistically significant variables at the α = 0.05 level.
To test our hypothesis regarding whether or not NDM patients received a significantly
different standard of care than DM patients, we performed a multivariate logistic regression. This
model looked at the dichotomous SOC variable as its outcome. As previously mentioned, all
three components of SOC needed to be delivered in order for us to consider that a patient
received the SOC for hyperglycemia. If only one or two components of SOC were delivered, we
determined that the patient did not receive the SOC for hyperglycemia. We took all of the
candidate variables from the bivariate regressions mentioned before and once again used
backward selection to obtain our multivariate logistic regression model. We removed all

covariates, one by one, until we were left with only the significant covariates (again, based on
the α = 0.05 significance level). Individual Chi-square and t-tests that showed significant
differences between diabetes status groups also provided us with more candidates to examine
during our logistic regressions.
We performed an extended Cox regression analysis to help us address our final
hypothesis regarding whether or not NDM patients waited significantly longer to receive insulin
after hyperglycemic trigger than DM patients. We calculated the number of minutes between the
time of hyperglycemic trigger (the point at which the first hyperglycemic blood glucose level
was measured in the perioperative period) and the time of first insulin administration. We also
calculated the time between the hyperglycemic trigger and hospital discharge. Our time-to-event
analysis used this time difference as the outcome variable. For those patients that did not receive
insulin (i.e. they did not have an insulin administration time), the time to censoring was the
length of time from trigger to hospital discharge. For the predictor variables, we started with
some that were deemed to be clinically important, as well as some variables that were deemed
significant in the final multivariate linear and logistic regression models. An automatic backward
selection for the Cox regression was run until we again were left with only significant factors at
the α = 0.05 significance level.
For each of the regression model processes, we tested certain clinically indicated oneway interaction terms. Individual statistical tests were examined to interpret the true effects of
these interactions (almost all of which were found to be statistically non-significant). It was
determined that no interactions warranted inclusion into any of our models. In addition to testing
interactions in each of our models, we used other statistical tests, diagnostic tools, AIC values

and Adjusted R2 values to help us find the models that were best-suited to help us address our
hypotheses.

Results
Important data set component variables are summarized as means, medians, and standard
deviations for continuous covariates; and as counts and percentages for categorical covariates. Pvalues are associated with the differences between the two diabetes status groups. Some factors
of interest that we examined, as well as the factors that were significant in each of our models,
are shown in Table 1.

Study results were divided into sections for each of our three hypotheses. Overall, our
final data set (n = 507) was evenly divided between DM patients (n = 268) and NDM patients (n
= 239). The study cohort contained a slightly larger number of males (n = 277) than females (n =
230); but there was no significant gender differences between the diabetes status groups. The

mean age of patients in the cohort was 62 years (SD = 13.8 years); with patients ranging from 19
to 93 years of age. Also, by far the largest race portion of the study cohort (95.46%) was white or
Caucasian (n = 450). Interesting to note (and a good indicator as to the even distribution of our
study cohort) was that there was no statistically significant difference between DM and NDM
patients for age (p = 0.319), gender (p = 0.541) and race (p = 0.430). In our study cohort, 47.14%
of all patients (n = 239), regardless of diabetes status, received the SOC for perioperative
hyperglycemia; with 48.13% of DM patients (n = 129) and 46.02% of NDM patients (n = 110)
receiving the SOC. Some components of the SOC for hyperglycemia variable were significantly
different between DM and NDM patients. However, when examining if all three components of
SOC were delivered (and thus, whether or not the SOC for hyperglycemia was delivered), there
was no statistically significant difference between DM and NDM patients (p = 0.657). Other
interesting things we noticed will be described in the results for each particular model.

Length of Stay (LOS) Outcome – Multivariate Linear Regression
Our first hypothesis examined if NDM patients had significantly longer average hospital
stays than DM patients. Looking at the diabetes status factor in our study cohort data set, we
found that the median LOS for DM patients in our sample was 132 hours (SD = 159.93); while
the median LOS for NDM patients was 174 hours (SD=242.01). Testing the significance of the
difference in the LOS distribution between groups, we considered that LOS was not normally
distributed and we ran a nonparametric Mann-Whitney U test. The test results indicated that
there indeed was a statistically significant difference between the underlying distributions of
LOS for DM and NDM patients (p < .0001). See the Appendix for box plots of the MannWhitney U test on LOS by diabetes status. Important to note is the presence of outliers in the

cohort, as a handful of patients had an LOS of 1,000 hours or longer. We have tried to take this
into consideration in our multivariate regression model by accounting for procedure length in
hours, which acts as a surrogate for surgery type. Thus we can take into account the lengths of
stay for those who had more serious and dangerous procedures. Therefore, we believe our model
accounts for these outliers by controlling for the seriousness of the surgical procedure.
There were several factors from bivariate analyses that were statistically significant
predictors of LOS; and thus became candidates for our final model. Our subject matter expert
determined that many of these variables would likely be highly correlated with our main
predictors. For example, there were several different insulin-related variables that were
independently significant predictors of LOS, such as those representing the different types of
insulin administered. Since insulin-related variables were basically a subset of our dichotomous
SOC variable, it was decided to only look at that overall SOC variable, and none of its related
components. Similar logic was used to make cases for omitting several other factors that were
initially qualified for inclusion in our final regression model. Also of note is that factors such as
gender, race, ethnicity, age and smoking status were all non-significant predictors of LOS from
our bivariate analyses. Thus none of these factors were included in our final, multivariate
regression model. With all that in mind, some important significant predictors of LOS from the
bivariate analyses follow. Surgical procedure duration in hours was independently significant (p
< .0001) in bivariate regression with LOS. In addition, steroid administration during hospital stay
(p = 0.026), steroid administration on the day of surgery (p = 0.033), standard of care delivery (p
= 0.022), and diabetes status (p < .0001) all were significant in bivariate regression with LOS.
The final model included the following significant variables that affect LOS: diabetes status (p <
.0001), standard of care provided (p = 0.0002), steroids given on day of surgery (p = 0.0086),

and procedure duration in hours (p < .0001). Model goodness-of-fit plots can be found in the
Appendix as well.
These results support our conjecture that NDM patients have significantly longer median
LOS than DM patients. In other words, we found that, when controlling for SOC administration,
steroid administration on the day of surgery, and length of surgical procedure, DM patients had
shorter LOS than NDM patients. The SOC variable was also significant in the model (p =
0.0002). This meant that when we controlled for diabetes status, procedure length and steroid
administration on the day of surgery, the absence of the delivery of the SOC for perioperative
hyperglycemia caused a longer-duration LOS than it would have been had SOC been delivered.
Since we hypothesized that both diabetes status and SOC would have an effect on LOS, and both
factors were significant predictors of hospital LOS, it appears we have statistical evidence
supporting our hypothesis.

Standard of Care (SOC) Outcome – Multivariate Logistic Regression
As previously noted, in order for the SOC to be delivered in cases of perioperative
hyperglycemia; (i) four times daily point of care blood glucose testing must have been ordered
within 24 hours of hyperglycemic trigger; (ii) basal (long-acting) insulin must have been
administered within 24 hours of trigger; and (iii) short-acting insulin must have been
administered within 24 hours of trigger. A patient was deemed to have been delivered the SOC
for hyperglycemia only if all three of the above events, (i) – (iii), occurred, according to the
medical record. If only one or two of these actions were taken, it was determined that the SOC
for hyperglycemia was not delivered.
Our second hypothesis aimed to see if there was a difference between DM and NDM
patients in how often they received the standard of care for hyperglycemia. Specifically, we

wanted to see if NDM patients received the standard of hyperglycemia care less often than DM
patients. In our full data set, the total number of patients receiving the standard for perioperative
hyperglycemia care was 239 (47.1%); which meant that 268 patients (52.9%) did not receive the
SOC. We did find that the SOC was delivered fairly equally among diabetes status groups. A
similar number and percentage of DM patients (n = 129; 48.1%) and NDM patients (n = 110;
46%) received SOC treatment for their hyperglycemia; while a similar number and percentage of
DM patients (n = 139; 51.9%) and NDM patients (n = 129; 54%) did not receive SOC treatment.
The estimated odds ratio (OR) of DM patients vs. NDM patients who received the SOC was
0.919 (p = 0.635). Thus, surprisingly we found that there was no statistically significant
difference regarding the delivery of SOC for perioperative hyperglycemia between the diabetes
status groups.
The first component that makes up our SOC variable (whether or not basal insulin was
administered to the patient within 24 hours of hyperglycemic trigger) was not a statistically
significant predictor, since the OR of DM patients versus NDM patients was 0.854 (p = 0.377).
In addition, we found that 50.4% of DM patients (n = 135) and 46.4% of NDM patients (n =
111) received basal insulin within 24 hours of hyperglycemic trigger. Next, we looked at the
component of SOC delivery that asked whether or not short-acting insulin was administered to
the patient within 24 hours of hyperglycemic trigger. In relation to diabetes status groups, we
found that 82.8% of DM patients (n = 222) received short-acting insulin within 24 hours of
hyperglycemic trigger; whereas only 64.4% of NDM patients (n = 154) received this component
of SOC. The OR of DM patients vs. NDM patients who received short-acting insulin within 24
hours of trigger was 0.375 (p < .0001). In this case, we indeed found a statistically significant
difference between DM and NDM patients. The third and final component of SOC delivery was

whether or not blood glucose monitoring was ordered for the hyperglycemic patient within 24
hours of trigger. Testing this component, we found similar results to the short-acting insulin
component. In relation to diabetes status groups, blood glucose monitoring was ordered for
89.9% of DM patients (n = 241); while only 76.2% of NDM patients (n = 182) received this
component of SOC. The OR of DM patients vs. NDM patients who received blood glucose
monitoring within 24 hours of trigger was 0.358 (p < .0001). Once again, we found an SOC
component where there was a statistically significant difference between DM and NDM patients.
This means that there were significant differences between diabetes status groups for two of the
three components of SOC delivery for hyperglycemia. However, as we have mentioned, all three
components must have been delivered to meet the SOC requirement. We somewhat surprisingly
found that there just was not a significant difference between diabetes status groups when all
three of the SOC components were considered together.
In our final model (with details shown in Table 2), we found that similar variables that
were significant in our multivariate linear regression model were also significant in our

multivariate logistic regression model. Procedure duration in hours (OR = 1.115; CI = 1.025 1.213; p = 0.0015) and steroid administration on the day of surgery (OR = 2.456; CI = 1.584 3.807; p < .0001) were both significant in the final model. An additional factor, the American

Society of Anesthesiologists Physical Status Classification (ASA class), was also significant.
ASA class was the only multi-category variable that was significant in any of our final models.
The OR for patients in the incapacitating disease class compared to patients in the mild systemic
disease class was 40.233 (CI = 8.403 - 192.635; p < .0001). The OR for patients in the severe
systemic disease class compared to patients in the mild systemic disease class was 5.231 (CI =
1.134 - 24.136; p = 0.648). The overall ASA class variable had a p-value < .0001; thus indicating
that, when controlling for diabetes status, duration of procedure, and steroid administration, ASA
class is significantly associated with SOC delivery. Surprisingly, diabetes status was not
significantly associated with SOC delivery: the OR was 0.835 (CI = 0.534 - 1.305) and the pvalue was 0.428. Again, we found this surprising, given that this hypothesis centered on the
belief that DM patients receive a different standard of hyperglycemic care than NDM patients.
However, our final model (with forced inclusion of diabetes status) showed us that at least in our
cohort, diabetes status was not significantly associated with whether or not a patient received the
standard of hyperglycemic care.

Time to Insulin Administration Outcome
Our final hypothesis examined whether or not NDM patients had to wait longer for
insulin administration after hyperglycemic trigger than DM patients. For this, we performed a
time-to-event analysis. We looked at the difference (in minutes) between the time of
hyperglycemic trigger to insulin administration as our time to event. We performed a log-rank
test to see if there was a significant difference in the time it took for insulin to be administered to
hyperglycemic DM patients and to hyperglycemic NDM patients. We found that the median time
from hyperglycemic trigger to insulin administration for DM patients (after censoring those
without insulin administration times) was 371 minutes. We also found that the median time from

hyperglycemic trigger to insulin administration for NDM patients was 4,122 minutes. This is
obviously quite a large difference. The low median for DM patients takes into account the fact
that, since these patients had diabetes, oftentimes insulin would be administered before there was
even a hyperglycemic trigger. Although many of the DM patients did not receive insulin until
after their trigger, many indeed received insulin long before; hence the low time difference
median. The high median time from trigger to insulin administration may be due to a couple of
outliers in the study cohort who received insulin 15,025 minutes and 25,837 minutes after
hyperglycemic trigger. But more important than focusing on the outliers is the fact that the
average time from trigger to insulin administration is much longer for NDM patients than it is for
DM patients. To check the statistical significance of this difference, we performed a log-rank
test. The results showed that the difference between DM and NDM patients in time to insulin
administration was indeed statistically significant (p = 0.0166). Since the difference was
significant and the median time to insulin administration was so much higher for NDM patients,
we uncovered some evidence to support the fact that hyperglycemic NDM patients generally
wait longer to receive insulin after first measured hyperglycemia than DM patients.
The time-to-event model involved the time from hyperglycemic trigger to first insulin
administration, regardless of the type of insulin administered (basal or short-acting). Looking
separately at those individual insulin types, we found something similar to what we saw
previously. Regarding basal insulin, we found that the median time from trigger to basal insulin
administration for DM patients was 1,371 minutes. While the median time from trigger to basal
insulin administration for NDM patients was 3,851 minutes. Just as before, there was quite a
longer median time that NDM patients waited for basal insulin administration than the time
waited for DM patients. This difference between groups was not statistically significant (p =

0.071). Looking at the time difference from hyperglycemic trigger to first short-acting insulin
administration, we saw similar results. The median time for DM patients was 401 minutes; while
the mean time to short-acting insulin administration for NDM patients was 381 minutes. Once
again, the difference between groups was statistically significant (p = 0.0042).
Finally, we tested an extended Cox regression model to find variables that may have been
associated with an increased time from hyperglycemic trigger to first insulin administration. The
model information is summarized in Table 3. We initially used the same key variables to start
our regression and performed
manual backward selection.
We eventually came up with
another model where, like our logistic regression with SOC as the outcome, we had to force
diabetes to stay in the model, as it was not a significant indicator of increased waiting time. This
was interesting, given that we found significant differences in time to insulin administration in
the individual analysis. Just as interesting was that if we performed our extended Cox regression
with just diabetes status as a predictor, diabetes status became significant. However, in our final
model, steroid administration on the day of surgery was found to be a significant predictor of
time to insulin administration (p < .0001). With that factor added in, diabetes status became
statistically non-significant (p = 0.608), while the hazard ratio for steroids not being administered
on the day of surgery compared to steroids being administered was 2.408 (CI = 1.887 - 3.075; p
< .0001). These results suggest that, when controlling for steroid administration on the day of
surgery, there is no statistically significant evidence to support our hypothesis that there is a
difference in the average time from hyperglycemic trigger to first insulin administration between
diabetes status groups.

Discussion
The results of our analyses revealed some interesting things; some of which we expected,
and some that we did not. In our study cohort, we found the degree of hyperglycemia was similar
between hyperglycemic DM patients and hyperglycemic NDM patients. We also discovered that,
as we hypothesized, the length of hospital stay was longer for hyperglycemic NDM patients than
it was for hyperglycemic DM patients. However, we additionally found that this increase in LOS
could not be explained by the appropriateness of treatment by either of two measures: one,
whether or not all components of standard of care were met; and two, the length of time from
hyperglycemic trigger to first insulin administration.
As we have previously noted, perioperative hyperglycemia has been associated with a
variety of adverse outcomes, including morbidity, post-operative infections, increased length of
hospital stay, and mortality (DeFelice & Thompson, 2016, Kwon et al, 2013, Umpierrez et al,
2011). We have also noted that increasing blood glucose levels have been shown to be directly
associated with increased hospital costs (Furnary, Wu & Bookin, 2004). Other complications
associated with perioperative hyperglycemia include acute respiratory failure, pneumonia, acute
renal failure, and stroke (Davis et al, 2018). In addition, there are several other examples in the
literature that show that perioperative hyperglycemia leads to a greater risk of adverse outcomes
in NDM patients when compared to DM patients. NDM patients have a significantly higher risk
of adverse events among all patients if they have any level of hyperglycemia in the perioperative
period (Kotagal et al, 2015). Also, NDM patients with perioperative hyperglycemia have nearly
two times the risk of re-operative interventions, infections, increased length of stay, and inhospital death than DM patients with this condition (Kwon et al, 2013). Our study seemed to
confirm the results of the previously cited research on differences in LOS between diabetes

status groups. Our multivariate linear regression with LOS as the outcome showed a significant
association with diabetes status. In that analysis, we saw that DM patients had shorter lengths of
hospital stay than NDM patients, when controlling for other factors such as standard of care.
We also believe that our study was unique in a couple of areas. None of the studies that
we cited or researched controlled for both steroid administration and SOC treatment of
hyperglycemia. Also, our full study cohort data set did not include just one type of surgery, as
did many of the other studies we reviewed. Indeed, the surrogate for type of surgery (procedure
duration in hours) was found to be a significant predictor of LOS in our multivariate linear
regression. So, we believe that not only did we support the conclusions of other studies regarding
LOS, but we also were able to look at perioperative hyperglycemia through a comparatively
different lens.
We have looked at some studies which concluded that there is a difference in adverse
outcomes, such as LOS, between patients with and without diabetes. But we have also noted the
possible mechanisms as to why NDM patients seem to have worse outcomes from perioperative
hyperglycemia. Some of the reasons stem from the differences in physiological response, such as
hyperglycemia possibly having a more pronounced effect on those without diabetes because it is
a novel stressor to them. Hence, those with diabetes may be more accustomed to the
inflammatory/oxidative effect of hyperglycemia. This also points to the idea that the degree of
physiological stress necessary to cause hyperglycemia may be greater in NDM patients (Kotagal
et al, 2015). We have also touched upon evidence from the literature, such as the study by Kwon
et al (2015), which posits that NDM patients might receive hyperglycemia care that is inferior to
the care received by DM patients with regards to the timeliness of insulin treatment, the standard
of care insulin regimens, and standard blood glucose monitoring.

In our study, standard of care monitoring was examined; which we believe makes ours
one of the first studies to address the underlying mechanisms of the differences between DM and
NDM patients. Though we did examine the SOC of hyperglycemia treatment, we did not find a
statistically significant difference in the SOC received by the diabetes status groups.
Management of hyperglycemia may still be the issue; but perhaps it is not the time to SOC blood
glucose monitoring and the time to insulin administration that are the key metrics. Perhaps the
key issues are more related to the insulin dose, the speed at which blood glucose is brought under
control, and/or how well blood glucose is controlled throughout the entire hospital admission.
Because we did not find the SOC for hyperglycemia to be significantly different between
diabetes status groups, we must conclude that one of the other physiological mechanisms is
responsible for the increased LOS for NDM patients.

Limitations
We acknowledge that several limitations to this study should be considered. In our study
cohort, we had only hyperglycemic DM and NDM patients. We did not have a comparison group
of patients without hyperglycemia. So, we could not address some of the issues discussed, like
the degree of physiological stress needed to cause hyperglycemia in NDM patients. There also
could have been an issue with selection bias, as we may have missed patients who had
hyperglycemia that was never detected during the course of their hospitalization. Also, many of
the patients in our study cohort without a formal diabetes diagnosis may in fact have had
undiagnosed diabetes. Or, there may have been patients who indeed had diabetes, but did not
have a diabetes diagnosis accessible in their medical record. For these patients, there may have
been some misclassification bias toward the null hypothesis in all analyses. Other limitations
include the fact that we did not study the dose of insulin or the degree of glucose control, which

both may be important measures of the effectiveness of hyperglycemia management. Also, since
this was a retrospective cohort study, our study design allowed for the possibility of unknown
and unmeasured confounders. Finally, our study cohort all came from the Nebraska Medical
Center, limiting the generalizability of our study results. Only 48.13% of the DM patients in the
cohort received the standard of hyperglycemic care. It may be harder to detect sub-standard care
for NDM patients when even more than half of the DM patients are receiving sub-standard care
for hyperglycemia as well.

Implications
Our single-center study on clinical care for hyperglycemia management shows that
standards of care are not being followed for the majority of patients, regardless of diabetes status.
There is opportunity for better adherence to standards of care, which would be expected to result
in improvement in outcomes (i.e., decreased mortality) that are important to patients.
We believe that further study on the hypotheses examined herein is warranted at other
institutions. Further research should also include the additional metrics of insulin dose, how
quickly blood glucose is brought under control, and how well blood glucose is controlled
throughout patient stay in the hospital. We also suggest that research into the physiologic
mechanisms underlying perioperative hyperglycemia should be undertaken. Important
mechanisms to be studied should, at the very least, include looking into the idea that DM patients
may be more accustomed to the inflammatory/oxidative effect of hyperglycemia than NDM
patients; and the idea that the degree of physiologic stress necessary to cause hyperglycemia may
be greater in NDM patients than in DM patients.

Conclusion
Perioperative hyperglycemia is common, even among patients without diabetes. We have
provided a litany of examples from the scientific literature that not only point out the host of
adverse outcomes that arise from perioperative hyperglycemia; but we have also provided ample
evidence that NDM patients experience the worst of these adverse outcomes when compared to
DM patients. In this study, we also found that perioperative hyperglycemia results in adverse
outcomes (e.g. increased LOS) that affect patients without diabetes to a greater degree than
patients with diabetes. Yet, when comparing diabetes status groups, we found no evidence to
support that the differences in the management of postoperative hyperglycemia are responsible
for the differences in adverse outcomes.
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